Sickle cell disease is one of the most common genetic diseases in the world, affecting one in every 10,000 people, according to the World Health Organization.
Now Abu Dhabi, the United Arab Emirates' capital, is teaming up with Pfizer to find a cure, the New York Times reports.
The emirate's Department of Health and Pfizer have signed a memorandum of understanding to use Abu Dhabi's "unique capabilities and future-forward data services as well as Pfizer's global capabilities" to study the disease, which affects one in every 10,000 people.
"By partnering with Pfizer on real-world data, we aim to improve healthcare prediction, prevention, personalized treatment, and access, not only benefiting healthcare professionals and patients in Abu Dhabi, but also contributing to the improvement of care for patients globally," says Dr. Asma Ibrahim Al Mannaei, executive director of Abu Dhabi's Research and Innovation Center, per a press release.
Pfizer's Gulf Cluster Lead, Serhat Yalcinkaya, adds in a statement: "Through this, we are committed to leveraging real-world data in the region and exploring further to other disease areas, ultimately improving patient outcomes and transforming Abu Dhabi into a global hub for life sciences."
The agreement will focus on collecting and analyzing real-world
A customized collection of grant news from foundations and the federal government from around the Web.
The government-backed Social Investment Research Council is newly formed to hatch practical insights into social investment market products, and the investors needed to finance them.